Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diazoxide choline extended-release
- Development stage
- Approved
- Lead developer
- Soleno Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DCCR is a novel, proprietary extended-release dosage form containing diazoxide choline, the crystalline salt of diazoxide. It is an ATP-dependent potassium channel agonist administered once daily. Developed by Soleno Therapeutics, it is the first FDA-approved treatment for hyperphagia in individuals with Prader-Willi syndrome (PWS) aged 4 years and older. In clinical trials, DCCR demonstrated significant reductions in hyperphagia, aggressive behaviors, anxiety, and compulsivity, while improving body composition and metabolic parameters.
- Brand names
- VYKAT XR
- Other names
- Diazoxide choline controlled release
02
Targets
KATP channel (ATP-sensitive potassium channel)SUR1 (Sulfonylurea receptor 1)
Beyond the preview
Go deeper on diazoxide choline extended-release.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diazoxide choline extended-release.